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Abstract		
The optimal healthy microbiota during early life still needs further evaluation. Pre- and probiotics 
are commonly used as supplementation in infant formula. Prebiotic oligosaccharides stimulate the 
growth of bifidobacteria aiming to mimic the gastrointestinal microbiota of breastfed infants. In 
general, results with prebiotics in therapeutic indications are disappointing. Studies suggest that 
probiotic supplementation may be beneficial in prevention and management of disease such as e.g., 
reducing the risk of necrotizing enterocolitis in preterm infants, prevention and treatment of acute 
gastroenteritis in infants, etc. Although many studies show promising beneficial effects, the long-
term health benefits and eventual risks of probiotic supplementation during early life are not clear.  
It is likely that ongoing research will result in the use of specific probiotic organisms and/or 
prebiotic oligosaccharides during the first 1,000 days of life, with the goal to develop a healthy 
microbiota from conception over birth into the first two years of life with a lowered risk of 
infections and inflammatory events.  
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When is infant microbiota optimal?  
 
The question arises immediately: do we know the 
optimal healthy gastro-intestinal (GI) microbiota 
for the infant and child? The answer is probably 
negative. The important differences between the GI 
microbiota development between infants born 
through cesarean section versus natural delivery or 
standard infant formula feeding versus 
breastfeeding are well known. We also know that 
the GI microbiota of the mother is influenced by 
medications (antibiotics, anti-acid medications, 
etc), diet, stress and many other factors.1 The GI 
microbiota of the breastfed baby born vaginally is 
in general considered as the “healthy microbiota”, 
but depends on the GI microbiota of the mother. 
More data need to be collected to better define the 
“optimal healthy GI microbiota”. The stepwise 
microbial gut colonization process may be initiated 
already prenatally by a distinct microbiota in the 
placenta and amniotic fluid.2 The clinical meaning 
of these findings needs to be further evaluated. A 
necrotizing enterocolitis (NEC) associated gut 
microbiota has been identified in meconium 
samples. Clostridium perfringens continues to be 
associated with NEC from the first meconium until 
just before NEC onset. In contrast, in post-
meconium, increased numbers of staphylococci 
were negatively associated with NEC.3 Pre-term 
birth, cesarean section, formula feeding, antibiotic 
use and malnutrition have been linked to dysbiosis, 
which in turn is associated with several pathologies 
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such as NEC, inflammatory bowel diseases, colic, 
and allergies. 
Probiotics are living microorganism that, 
when administered in sufficient amount, have a 
health benefit for the host. Prebiotics are non-
digestible food ingredients that beneficially affect 
the host by selectively stimulating the growth 
and/or activity of one or a limited number of 
bacteria in the colon, which can improve host 
health. Synbiotics are a mixture of pre- and 
probiotics.  
Based on the current literature, a case can 
be made for the use of specific sets of probiotic 
organisms with the goal of promoting a healthy 
pregnancy to birth, and a healthy start to life with 
lowered risk of infections and inflammatory 
events.4 The mechanisms of specific probiotic 
strains administered during the perinatal period 
suggest that probiotic interventions in early life can 
be envisaged for disease prevention in both healthy 
offspring and offspring at risk of chronic disease. 
There is evidence that manipulation of the infant 
microbiota by using pre- or probiotics can restore 
the ecological balance of the microbiota and may 
mitigate potential negative effects on the 
developing immune system, when use of antibiotics 
cannot be avoided.5 
 
Probiotics 
 
Unfortunately, the term "probiotic" seems to cause 
confusion. The taxonomic ranking for classification 
of probiotics is as follows: there is a domain 
(bacteria, fungi), a lineage (eg Furmicutes), a class 
(eg Lactobacilli), an order (eg Lactobacillales), a 
family, a genus, a species and subspecies. Most 
probiotics are bacteria, but the yeast 
Saccharomyces boulardii is one of the best studied, 
especially in gastroenterologic indications (Fig 1). 
Probiotics do not colonize the host. This means, 
that one to two weeks after stopping the 
administration of a probiotic strain, it disappears 
from the GI microbiota. The European Food Safety 
Authority considers "probiotics" as a medical 
claim, what results in the prohibition of the term on 
products or for communication by companies. 
More and more patents are given to  specific  
probiotics  with  specific claims:   fat  metabolism,  
obesity,  oral health,   anticancer  treatments, 
cardiovascular disorders, diabetes,  
immunomodulation,  allergy, viral diseases such as 
AIDS, and others. A lot of research on probiotics is 
now focusing on other areas such as veterinary 
medicine and dermatology.  
Traditional cuisines do contain a lot of 
fermented foods and thus probiotics. Fermented 
foods are foods produced or preserved by the action 
of microorganisms. The use of bacteria such as 
Lactobacillus results in the making of foods such as 
yoghurt and sauerkraut. The science of 
fermentation is known as zymology. Many pickled 
or soured foods are fermented as part of the 
pickling or souring process.  
The market is overloaded with food 
supplements containing probiotics. However, there 
is no guarantee for the quality of such a product. 
There can be problems at the manufacturing level, 
but also at the level of survival during shelf life, or 
poor resistance to gastric acid.6–8 In other words, 
there is a world of difference between using 
probiotics as a healthy eating habit or using 
probiotics as medication.  
Figure 1 Illustration of the size difference between 
a yeast probiotic (Saccharomyces boulardii) and  
bacteria (Salmonella) 
 
Probiotics can just be added to food, such as 
in infant formula. Probiotics are also added to 
foods such as chocolate and ice cream. Many  
yoghurts are enriched with probiotics. However, it 
is obvious that the targeted effect of probiotics in 
food differs in both situations substantially: while 
in infant formula there is a clear medical purpose, 
probiotics added to food such as ice cream and 
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chocolate have a merely marketing goal claiming to 
improve general wellbeing. Probiotics used for 
medical purposes are often commercialized as pills 
or sachets. Some products are also on the market in 
liquid form and are administered as drops. Slow 
release tablets (e.g. to be put in a specially designed 
infant pacifier) were developed.9 Especially for 
respiratory tract indications, probiotics sprays have 
been developed.10 A novel probiotic delivery 
system has been developed in which probiotics are 
grown as a biofilm on microspheres, allowing 
enhanced efficacy with only a single treatment.11 
It is beyond doubt that for specific medical 
purposes the effect of probiotic is strain-specific. 
This is illustrated by the following findings. 
Breastfeeding women received probiotic milk or 
placebo from 36 weeks of gestation up to 3 months 
postnatally while breast-feeding.12 The probiotic 
milk contained Lactobacillus (L.) rhamnosus GG, 
L. acidophilus La-5, and Bifidobacterium animalis 
subsp. lactis Bb-12. Only the L. rhamnosus GG 
bacteria colonized the children at 10 days and at 3 
months of age.12 Different probiotic bacteria seem 
to have different ability to transfer from the mother 
to the child. This is in line with the finding that L. 
rhamnosus strains present in breastmilk were 
isolated and characterized and should be further 
characterized.13 However, the relevance of strain 
specificity depends on the probiotic property that is 
looked for. Lactobacilli that survive gastric acid 
and bile will be fermented in the colon. Depending 
on the effect that is looked for, strain specificity is 
more or less important. The impact of probiotics on 
the development of the immune system in formula 
fed infants was recently illustrated by the findings 
of the TEDDY study.14 Early probiotic 
supplementation (at the age of 0–27 days) was 
associated with a decreased risk of islet 
autoimmunity when compared with probiotic 
supplementation after 27 days or no probiotic 
supplementation.14 It was concluded that early 
probiotic supplementation may reduce the risk of 
islet autoimmunity in children at the highest 
genetic risk of diabetes.14 
Many probiotic products are a combination 
of different strains. However, multi-species can as 
well do better than worse as single strains 
products.15,16 In general, high dosages are more 
effective than low, although the number of dose-
efficacy studies is limited.17 Although, some meta-
analyses come exactly to the opposite conclusions: 
in patients with irritable bowel syndrome, single 
probiotics at a low dose and with a short treatment 
duration appear to be more effective in improving 
overall symptom response and quality of life.18 
Older literature also suggest that the earlier 
probiotics are started (in the treatment of acute 
gastroenteritis), the greater the effect.19  
In general, probiotics have the label to be 
"GRAS" (generally regarded as safe). However, 
side effects, mostly sepsis, are reported. But, 
probiotics have also been used safely in patients 
with immune deficiencies, showing a beneficial 
effect on growth only in HIV-positive infants.20 
The increased use of probiotics in vulnerable 
immune insufficient preterm infants may lead to an 
increased risk of severe complications such as 
sepsis with the probiotic.21 
Although generalization should be avoided, 
as efficacy for medical indications is strain specific, 
it can be said that there is evidence that some 
strains do prevent atopic dermatitis (especially if 
also given to the mother during pregnancy). To 
date, expert bodies do not generally recommend 
probiotics for allergy prevention, although the 
World Allergy Organization (WAO) in their 
recently developed guidelines suggests considering 
using probiotics in pregnant women, during 
breastfeeding and/or to the infant if at high risk of 
developing allergic disease (based on heredity).22 
However, in concordance with other expert bodies, 
the WAO guideline panel stressed the low level of 
evidence and the need for adequately powered 
randomized controlled trials and a more 
standardized approach before clinical 
recommendations on specific strains, dosages and 
timing can be given.22 Several meta-analyses have 
reported a moderate benefit of probiotics for 
eczema prevention, and the most consistent effect 
has been observed with a combined perinatal 
intervention in infants at high risk of allergic 
disease due to familial predisposition.22 Multi-
strain probiotics appeared to be most effective for 
eczema prevention.22 
Probiotic strains have also been shown to 
prevent infectious disease such as community
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acquired and nosocomial gastroenteritis, respiratory 
tract and urinary tract infections. Infants receiving 
Bifidobacterium BB-12 were reported to have 
experienced fewer respiratory tract infections (risk 
ratio (RR): 0.87; 95% confidence interval (CI): 
0.76, 1.00; p=0.033) than controls.23 No significant 
differences between the groups were observed in 
reported GI symptoms, otitis media, or fever.23  
Probiotics also decrease the incidence and 
severity of NEC in preterms. Strategies such as 
antenatal glucocorticoids, postnatal breast milk 
feeding, and cautious approach to enteral feeding 
failed to eliminate NEC because these strategies 
did not address the complexity of the 
pathogenesis.24 Probiotics seem to be the most 
significant advance in NEC prevention at present 
because of the significant range of beneficial 
effects at various levels of gut function and defense 
mechanism.24 However not all studies are positive, 
as shown by a study with B breve BBG-001 for 
prevention of NEC and late-onset sepsis in very 
preterm infants.25 New ways of administration of 
probiotics are developed, specifically for preterm 
infants.26 A single dose of Lactobacillus biofilm 
grown on biocompatible microspheres was shown 
to significantly reduce NEC incidence and severity 
in rats.26 Therefore, the risk/benefit should be 
considered before starting routine administration. 
Standard care in the Neonatal Intensive Care Units 
in the western world has resulted in a very low 
incidence of NEC. Oral probiotic given to VLBW 
infants do not affect neuromotor, neurosensory and 
cognitive outcomes at 18–24 months' corrected 
age.27 Rapid changes of nasogastric tubes may lead 
to a decreased incidence of NEC without the risk 
for sepsis.28 
Probiotics also shorten the duration of 
infectious diseases, such as gastroenteritis. 
Probiotics added to infant formula have been 
shown in many older studies to possibly protect for 
infectious gastroenteritis, although some studies did 
not show a benefit. However, there was no study 
that suggested an increased risk of gastroenteritis. 
They are also effective in the prevention and 
treatment of antibiotic associated diarrhea (AAD). 
Moderate quality evidence suggests a protective 
effect of probiotics in preventing AAD (RR 0.46; 
95% CI 0.35 to 0.61), with a number needed to 
treat of 10.29  
Probiotics may also have a role in infantile 
colic and in irritable bowel syndrome, especially 
older children and adults. The management of 
infantile colic in formula fed infants is still a 
challenge. L. reuteri DSM 17938 was ineffective in 
formula fed infants.30 L. GG in infants treated in 
tandem with behavioral support and a cow's milk 
elimination diet did not provide additional 
treatment effect for diary-verified colic crying 
although parental report of crying suggested the 
probiotic intervention effective.31 A synbiotic (a 
mixture of seven probiotic strains plus FOS 
(Fructooligosaccharide)) significantly improved 
colic symptoms in comparison with placebo.32 
Several studies were performed with L. reuteri 
DSM 17938 in breastfed infants presenting with 
infantile colic.33   
Probiotics may also decrease regurgitation. 
Treated infants demonstrated a reduction in daily 
regurgitations at the end of treatment, three 
neonates in the placebo group only needed 
simethicone for GI pain, sIgA level was similar in 
both groups.34 
Probiotics result in a 10% eradication rate 
of Helicobacter pylori infection, although it is not 
known whether this is due to a true better 
eradication or better compliance to the eradication 
treatment because of a decrease of adverse effects 
(antibiotic associated diarrhea). Probiotics have 
been shown to be effective in the treatment of 
constipation in adults, but not in children. 
Literature on the efficacy of probiotics in 
inflammatory bowel disease is in general 
disappointing, certainly in pediatrics. The above list 
is not exhaustive, but indicates the broad spectrum 
of possible indications, going from general 
wellbeing over immune mediated diseases to 
infections. But negative results have also (seldom) 
been reported. Lactobacillus acidophilus (LAVRI-
A1) was reported to increase the risk of atopic 
dermatitis compared to placebo.35 
 
Probiotics during pregnancy  
 
Probiotics administered during pregnancy (and 
breastfeeding) to the mother can be found in the GI 
microbiota of the woman and has been shown for 
some strains to possibly have a preventive effect of 
the frequency and severity of atopic dermatitis in 
the infant. However, the literature on the effect of 
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probiotics on the infant when given to the mother 
during pregnancy is quiet contradictory. According 
to some authors, currently evidence does not 
indicate that probiotic supplementation reduces the 
risk of developing allergy in children. 
Current analysis of the role of probiotics in 
the prevention of atopic dermatitis reveals that a 
positive effect may be related to the type of 
probiotic strain used, the method of administration, 
onset time, as well as the dose size and duration of 
treatment.36 Panduru et al.37 concluded in a meta-
analysis that probiotics have a protective role in 
atopic dermatitis prevention if they are 
administered during the pre- and postnatal period, 
in both the general and at allergic risk population. 
Maternal probiotic ingestion alone may be 
sufficient for long-term reduction in the cumulative 
incidence of atopic dermatitis, but not other allergy 
related diseases.38 The guideline of the World 
Allergy Organisation (WAO) panel determined that 
there is a likely net benefit from using probiotics 
resulting primarily from prevention of eczema. The 
WAO guideline panel suggests: a) using probiotics 
in pregnant women at high risk for having an 
allergic child; b) using probiotics in women who 
breastfeed infants at high risk of developing 
allergy; and c) using probiotics in infants at high 
risk of developing allergy. All recommendations 
are conditional and supported by very low quality 
evidence.39 
 
Prebiotics 
 
Many of the production and conservation 
difficulties such as survival during production and 
shelflife with probiotics are not valid for prebiotics. 
Prebiotics stimulate the GI microbiota of the host, 
whereas probiotics just add one or couple of 
strains. According to some data, they may have 
prolonged effect. Some data suggest that if infant 
are supplemented from birth up to six months, that 
the bifidogenic effect can still be observed at the 
age of 12 months.40 Also prebiotics are generic, and 
findings of one prebiotic cannot be extrapolated to 
another one.41 The number of comparative and 
dose-efficacy studies is extremely limited.  
The advantages of prebiotics in infants and 
children are mostly limited to prevention studies 
with infant formula supplemented with prebiotics 
oligosaccharides. While some studies show a 
benefit, others fail to do so, but the outcome in the 
prebiotic group is never worse than the comparator 
group. Most studies on the efficacy of prebiotics in 
therapeutic indications are disappointing. The 
effect of some prebiotic oligosaccharides on the 
gastro-intestinal microbiota is clear, as the effect on 
stool frequency and composition in non-constipated 
infants, bringing defecation pattern in formula fed 
infants closer to the pattern in breastfed infants. 
Literature is not conclusive on other possible 
effects such as decrease of infection, decrease of 
atopic dermatitis, and so on. Compared to 
probiotics, for which side effects are scarce but 
reported, adverse effects of prebiotics in infants are 
not reported.  
 
Synbiotics 
 
Data on the combination of pre- and probiotics in 
infants and children are quiet limited. Most studies 
regard short-term therapeutic interventions. 
Mean ± standard deviation infection rates in infants 
followed up to 12 months were 4.9 ± 3.2 per infant 
per year in the B.lactis + GOS (Galacto-
oligosaccharide)/FOS group and 4.5 ± 3.0 per infant 
per year in the B lactis group (p = 0.18). Mean daily 
weight gain was slightly lower in the 
B.lactis + GOS/FOS than the B lactis group 
(16.1 ± 2.9 vs 16.6 ± 2.6 g/day, p = 0.046), but was 
not clinically significant.42 Other outcomes were 
not significantly different between groups. 
Formulas containing B.lactis + GOS/FOS did not 
reduce infection rates beyond those containing only 
B lactis.42 Chang et al.43 conclude in their meta-
analysis that evidence  supports the use of 
synbiotics for the treatment of atopic dermatitis, 
particularly synbiotics with mixed strains of 
bacteria and for children aged 1 year or older. 
Nevertheless, infant formula companies promote 
the combination of pre- and probiotics in infant 
formula. Although this evolution does not seem to 
induce any increased risk for adverse effects, the 
benefit has not been shown.  
 
Conclusion 
 
The knowledge on the importance of the GI 
microbiota to the development of wellbeing and 
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general health is increasing, and has been a focus of 
research during the past 10 years. The development 
of a healthy GI microbiota from conception 
throughout the first years of life will have lifetime 
long consequences. The use of prebiotics, 
probiotics and synbiotics in the prevention and 
treatment of different health conditions is 
increasing. If probiotic and prebiotic products are 
intended to be used in medical indications with the 
intention to claim a health benefit, at least two 
independent clinical studies are needed with the 
commercialized product. If products are 
commercialized with the intention to contribute to 
healthy eating habits, such high quality research is 
not needed. However, in that case, it is not justified 
to have any claim. In order to reduce confusion, a 
different terminology for "healthy foods with pre- 
and probiotics" and "specific products claiming a 
targeted health benefit"  would be welcomed. The 
earlier proposed term "biotherapeutic agent" does 
not fulfill the requirements, as the concerned 
effects regard also prevention, probably even more 
than therapy.  
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